CellCarta Establishes Strategic Partnership with Waters to Advance Companion Diagnostics Development
Collaboration combines CellCarta's global clinical trial testing capabilities with Waters' standardized flow cytometry platforms and expertise MONTREAL, Oct. 5, 2026 /PRNewswire/ -- CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic...
Covered in this story
What has happened since
- Waters Corporation is up 0.6% since this was published, 15 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Waters Corporation
- TD Cowen: $400 → $475 by Aug 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $WAT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Waters Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.